Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.

Tricoci P, D'Andrea DM, Gurbel PA, Yao Z, Cuchel M, Winston B, Schott R, Weiss R, Blazing MA, Cannon L, Bailey A, Angiolillo DJ, Gille A, Shear CL, Wright SD, Alexander JH.

J Am Heart Assoc. 2015 Aug 25;4(8):e002171. doi: 10.1161/JAHA.115.002171.

2.

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Review.

3.

Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.

Miyares MA, Davis K.

Vasc Health Risk Manag. 2012;8:483-93. doi: 10.2147/VHRM.S29010. Epub 2012 Aug 23. Review.

4.

Lipid clinics are urgently required in the Iranian public health system.

Ghayour-Mobarhan M, Kazemi-Bajestani SM, Ferns G.

Int J Prev Med. 2010 Summer;1(3):172-5.

5.

Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD.

Matthan NR, Pencina M, LaRocque JM, Jacques PF, D'Agostino RB, Schaefer EJ, Lichtenstein AH.

J Lipid Res. 2009 Sep;50(9):1927-35. doi: 10.1194/jlr.P900039-JLR200. Epub 2009 May 12.

6.

No effect of low-dose statins treatment on cerebral blood flow in humans with atherosclerotic cerebrovascular disease.

Derdeyn CP, Carpenter DA, Videen TO, Grubb RL Jr, Powers WJ.

J Cereb Blood Flow Metab. 2007 Sep;27(9):1643-8. Epub 2007 Mar 14.

7.

Development and validation of the hyperlipidemia: attitudes and beliefs in treatment (HABIT) survey for physicians.

Foley KA, Vasey J, Alexander CM, Markson LE.

J Gen Intern Med. 2003 Dec;18(12):984-90.

9.

Risk factor thresholds: their existence under scrutiny.

Law MR, Wald NJ.

BMJ. 2002 Jun 29;324(7353):1570-6. Review. No abstract available.

10.

National service framework for coronary heart disease. Ambiguities need to be clarified.

Lloyd-Mostyn R.

BMJ. 2000 Sep 9;321(7261):634. No abstract available.

12.

Supplemental Content

Support Center